The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.
( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first ...
The FDA has approved Vertex Pharmaceuticals’ Journavx, a new pain medication designed to reduce the risk of addiction and overdose associated with opioids. Intended for short-term pain after surgeries ...
The drug is called Journavx and doctors believe it has no potential for addiction and dependence.
The US Food and Drug Administration has approved the first-ever non-opioid pain reliever in more than two decades.According ...
Vertex Pharmaceuticals’ suzetrigine gets US FDA approval for treatment of adults with moderate-to-severe acute pain: Boston Saturday, February 1, 2025, 14:00 Hrs [IST] Vertex Ph ...
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares. Vertex’s suzetrigine, branded Journavx, was recently ...
The US Food and Drug Administration (FDA) has approved a new pain medication, suzetrigine, marking the first new type of pain reliever to be approved in over 20 years.The drug, sold under the brand ...
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
On Thursday, the Food and Drug Administration approved the non-opioid pain relievers from Vertex Pharmaceuticals, a new ...